Target NET: Investigation of the molecular, immunological and genetic features associated with neuroendocrine tumour dissemination, progression and response to treatment.

What is the purpose of this study?

Neuroendocrine Tumours (NETs) are relatively rare in our population. We are a specialist service for the treatment of NETs, and we are always looking to improve on the treatments we provide. To do this we need to understand more about NETs; particularly why they occur and what promotes their development. This greater understanding will hopefully permit us to develop improved treatments in the future. The research will involve studying tissue samples from patients who are undergoing investigation or treatment for NETs. These samples will be examined in detail for the molecular, immunological and genetic changes that have occurred for NET to develop, and also for the body’s immune response to the disease.
This study is being organised by doctors and scientists from University Hospital Southampton/University of Southampton in partnership with experienced doctors and scientists from other Universities, Hospitals and Laboratories. Funding is through research grants held by the investigators, in particular the Southampton NIHR Experimental Cancer Medicine Centre funded by Cancer Research UK and the UK Department of Health, PLANETS and the Robert White fund. The doctors conducting the study are not being paid to do so.
In layman’s terms, because neuroendocrine tumours are relatively rare, not enough is known about them. However, Southampton is very unique in the sense that we have been very involved with treating patients with NETs and now have a vast experience in dealing with them with a specialised MDT team and a large number of patients with experience of living with NETs.
TARGET NET is asking patients if we can take some tissues (both normal and the neuroendocrine tissue) when they have surgery. We want to be able to store them (for studies now, and being carried out in future), and also run lots of complicated experiments and tests on them.  We will also be running experiments to see what kind of relationship NETs have with the immune cells. There are new emerging cancer drugs that ‘boost’ your immune cells into fighting the tumour cells. We want to see if NETs could be the type of cancer we can treat with this new form of treatment in the future.
In the background of all of this, running different experiments and genetic studies on the samples will also help understand NETs as a whole and why they are so special and different to other types of cancers so that we can educate and improve the information we give when patients are diagnosed with NETs.